Sector News

Regeneron’s Eylea snags pre-filled syringe approval as Novartis rival looms

August 14, 2019
Life sciences

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?

That’s what Regeneron’s hoping. The FDA Tuesday approved a new pre-filled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a pre-filled injector, and the newest green light should help it secure its place as the top-performing wet AMD drug on the market as competitors loom.

Novartis’ brolucizumab, a wannabe rival in wet AMD, is under priority review from the FDA, and it could steal the limelight from Eylea and its only approved competitor, Roche’s Lucentis. Novartis’ drug boasts strong head-to-head data against Eylea, including wins against the older drug in reducing retinal fluid and central subfield thickness.

But Regeneron hasn’t taken that challenge sitting down. In May, Eylea received an FDA nod to treat all forms of diabetic retinopathy, a condition that affects about 8 million people worldwide and is the leading cause of blindness in U.S. adults, the company said.

That new indication helped drive Eylea sales up 17% in the second quarter to $1.16 billion. Those sales represent a significant chunk of the drugmaker’s total $1.9 billion in the quarter.

It also followed positive results from the drug’s phase 3 trial dubbed Panorama, which showed an 85% and 88% risk reduction for diabetic retinopathy patients developing proliferative diabetic retinopathy (PDR) at the one-year mark when dosing every 16 and eight weeks, respectively. Twenty percent of untreated patients developed PDR, which causes abnormal blood vessel growth on retinas and potentially vision loss, at the one-year mark, the company said.

Strong sales have been a boon for Regeneron as another pillar of its growth strategy—an antibody partnership with Sanofi on PCSK9 inhibitor Praluent and Dupixent—is just now turning a profit.

Fueled by Dupixent’s $557 million in second-quarter sales—a 166% increase—Regeneron last week reported that its Sanofi partnership posted a $39 million profit, a big turnabout from the same period last year, when it cost Regeneron $69 million.

By: Kyle Blankenship

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach